These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 18768809)

  • 1. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.
    Fujishita T; Aoki K; Lane HA; Aoki M; Taketo MM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13544-9. PubMed ID: 18768809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mTORC1 pathway in intestinal tumorigenesis.
    Fujishita T; Aoki M; Taketo MM
    Cell Cycle; 2009 Nov; 8(22):3684-7. PubMed ID: 19855161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic mutations in adenomatous polyposis coli (Apc) activate mechanistic target of rapamycin complex 1 (mTORC1) in mice and zebrafish.
    Valvezan AJ; Huang J; Lengner CJ; Pack M; Klein PS
    Dis Model Mech; 2014 Jan; 7(1):63-71. PubMed ID: 24092877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice.
    Aoki K; Tamai Y; Horiike S; Oshima M; Taketo MM
    Nat Genet; 2003 Dec; 35(4):323-30. PubMed ID: 14625550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of intestinal adenoma formation in APC(Min/+) mice by Riccardin D, a natural product derived from liverwort plant Dumortiera hirsuta.
    Liu HP; Gao ZH; Cui SX; Sun DF; Wang Y; Zhao CR; Lou HX; Qu XJ
    PLoS One; 2012; 7(3):e33243. PubMed ID: 22432006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.
    Pollizzi K; Malinowska-Kolodziej I; Stumm M; Lane H; Kwiatkowski D
    Mol Cancer; 2009 Jun; 8():38. PubMed ID: 19527517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JNK signaling promotes intestinal tumorigenesis through activation of mTOR complex 1 in Apc(Δ716) mice.
    Fujishita T; Aoki M; Taketo MM
    Gastroenterology; 2011 May; 140(5):1556-63.e6. PubMed ID: 21320501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
    Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced level of smoothened suppresses intestinal tumorigenesis by down-regulation of Wnt signaling.
    Arimura S; Matsunaga A; Kitamura T; Aoki K; Aoki M; Taketo MM
    Gastroenterology; 2009 Aug; 137(2):629-38. PubMed ID: 19427313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.
    Thiem S; Pierce TP; Palmieri M; Putoczki TL; Buchert M; Preaudet A; Farid RO; Love C; Catimel B; Lei Z; Rozen S; Gopalakrishnan V; Schaper F; Hallek M; Boussioutas A; Tan P; Jarnicki A; Ernst M
    J Clin Invest; 2013 Feb; 123(2):767-81. PubMed ID: 23321674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin inhibition of polyposis and progression to dysplasia in a mouse model.
    Hardiman KM; Liu J; Feng Y; Greenson JK; Fearon ER
    PLoS One; 2014; 9(4):e96023. PubMed ID: 24763434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1-mediated translational elongation limits intestinal tumour initiation and growth.
    Faller WJ; Jackson TJ; Knight JR; Ridgway RA; Jamieson T; Karim SA; Jones C; Radulescu S; Huels DJ; Myant KB; Dudek KM; Casey HA; Scopelliti A; Cordero JB; Vidal M; Pende M; Ryazanov AG; Sonenberg N; Meyuhas O; Hall MN; Bushell M; Willis AE; Sansom OJ
    Nature; 2015 Jan; 517(7535):497-500. PubMed ID: 25383520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The threshold level of adenomatous polyposis coli protein for mouse intestinal tumorigenesis.
    Li Q; Ishikawa TO; Oshima M; Taketo MM
    Cancer Res; 2005 Oct; 65(19):8622-7. PubMed ID: 16204028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer.
    Metcalfe C; Ibrahim AE; Graeb M; de la Roche M; Schwarz-Romond T; Fiedler M; Winton DJ; Corfield A; Bienz M
    Cancer Res; 2010 Aug; 70(16):6629-38. PubMed ID: 20663899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A knock-in mouse model reveals roles for nuclear Apc in cell proliferation, Wnt signal inhibition and tumor suppression.
    Zeineldin M; Cunningham J; McGuinness W; Alltizer P; Cowley B; Blanchat B; Xu W; Pinson D; Neufeld KL
    Oncogene; 2012 May; 31(19):2423-37. PubMed ID: 21996741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.
    Guigon CJ; Fozzatti L; Lu C; Willingham MC; Cheng SY
    Carcinogenesis; 2010 Jul; 31(7):1284-91. PubMed ID: 20299527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps.
    Seno H; Oshima M; Ishikawa TO; Oshima H; Takaku K; Chiba T; Narumiya S; Taketo MM
    Cancer Res; 2002 Jan; 62(2):506-11. PubMed ID: 11809702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
    Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
    PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.